Ptc Therapeutics (PTCT) Change in Accured Expenses (2012 - 2026)

Ptc Therapeutics' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 404.15% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was $69.9 million, a 346.17% increase from a year earlier, with the FY2025 full-year figure at $71.7 million, up 315.3% from the prior year.
• Change in Accured Expenses fell to -$2.3 million in Q1 2026 per PTCT's latest filing, from $98.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $98.2 million in Q4 2025 and bottomed at -$33.4 million in Q3 2025.
• The 5-year median for Change in Accured Expenses is -$458000.0 (2025), against an average of $6.6 million.
• Across the five-year window, Change in Accured Expenses surged 710.03% in 2023 and slumped 1712.11% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $26.0 million in 2022, then sank by 69.54% to $7.9 million in 2023, then tumbled by 461.34% to -$28.6 million in 2024, then surged by 443.62% to $98.2 million in 2025, then sank by 102.35% to -$2.3 million in 2026.
• Per Business Quant, the three latest PTCT Change in Accured Expenses figures stand at -$2.3 million (Q1 2026), $98.2 million (Q4 2025), and -$33.4 million (Q3 2025).